Thinking with Sound: Exploring the Experience of Listening to an Ultrasonic Art Installation

Entanglement theories are well established in HCI discourse. These involve a commitment to view human experience in encounters with technology as relational and contingent, and research appara- tuses as co-producers rather than passive observers of phenomena. In this paper, we argue that sound is the sensory modality best suited to the investigation of entanglements. Materialist theories of sound and listening guide both the design of a novel interactive sound installation and the methodological approach of a participant study exploring the experience of listening. We present a diffrac- tive analysis whereby micro-phenomenological interview data is read with sonic theories, generating accounts that might other- wise remain mute: the temporal fluctuation and physical feeling of proximity in listener entanglements with sound, somatic intention setting, and plural interpretations of interactivity. Finally, we offer a series of provocations for HCI to embrace qualities of the sonic and consider epistemological positions grounded in other sense modalities

Treatment of lupus nephritis with abatacept: the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study

OBJECTIVE: To assess the efficacy and safety of a 24-week course of abatacept in the treatment of active lupus nephritis and to assess the potential of abatacept to induce clinical tolerance, defined as sustained clinical quiescence of lupus nephritis after discontinuation of immunosuppressive therapy. METHODS: Patients with active lupus nephritis (n = 134) were enrolled in a randomized, double-blind phase II add-on trial in which they received either abatacept or placebo in conjunction with the Euro-Lupus Nephritis Trial regimen of low-dose cyclophosphamide (CYC) followed by azathioprine (AZA). The primary efficacy outcome was the frequency of complete response at week 24. Thereafter, patients who met either complete or partial response criteria continued blinded treatment through week 52. During this phase of the study, subjects in the abatacept treatment group in whom a complete response was achieved at week 24 discontinued immunosuppressive therapy other than prednisone (10 mg/day). RESULTS: There were no statistically significant differences between groups with respect to the primary outcome or any of the secondary outcomes, including measures of safety. A complete response was achieved in 33% of the subjects in the treatment group and in 31% of the subjects in the control group at week 24. Fifty percent of the subjects in the treatment group who met complete response criteria and therefore discontinued immunosuppressive therapy at week 24 maintained their complete response status through week 52. CONCLUSION: The addition of abatacept to a regimen of CYC followed by AZA did not improve the outcome of lupus nephritis at either 24 or 52 weeks. No worrisome safety signals were encountered

Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn\u27s Disease But Not Ulcerative Colitis.

BACKGROUND & AIMS: Patients with Crohn\u27s disease (CD), but not ulcerative colitis (UC), of shorter duration have higher rates of response to tumor necrosis factor (TNF) antagonists than patients with longer disease duration. Little is known about the association between disease duration and response to other biologic agents. We aimed to evaluate response of patients with CD or UC to vedolizumab, stratified by disease duration. METHODS: We analyzed data from a retrospective, multicenter, consortium of patients with CD (n = 650) or UC (n = 437) treated with vedolizumab from May 2014 through December 2016. Using time to event analyses, we compared rates of clinical remission, corticosteroid-free remission (CSFR), and endoscopic remission between patients with early-stage (≤2 years duration) and later-stage (\u3e2 years) CD or UC. We used Cox proportional hazards models to identify factors associated with outcomes. RESULTS: Within 6 months initiation of treatment with vedolizumab, significantly higher proportions of patients with early-stage CD, vs later-stage CD, achieved clinical remission (38% vs 23%), CSFR (43% vs 14%), and endoscopic remission (29% vs 13%) (P \u3c .05 for all comparisons). After adjusting for disease-related factors including previous exposure to TNF antagonists, patients with early-stage CD were significantly more likely than patients with later-stage CD to achieve clinical remission (adjusted hazard ratio [aHR], 1.59; 95% CI, 1.02-2.49), CSFR (aHR, 3.39; 95% CI, 1.66-6.92), and endoscopic remission (aHR, 1.90; 95% CI, 1.06-3.39). In contrast, disease duration was not a significant predictor of response among patients with UC. CONCLUSIONS: Patients with CD for 2 years or less are significantly more likely to achieve a complete response, CSFR, or endoscopic response to vedolizumab than patients with longer disease duration. Disease duration does not associate with response vedolizumab in patients with UC

Eikonal representation in the momentum-transfer space

By means of empirical fits to the differential cross section data on pp and p(bar)p elastic scattering, above 10 GeV (center-of-mass energy), we determine the eikonal in the momentum - transfer space (q^2- space). We make use of a numerical method and a novel semi-analytical method, through which the uncertainties from the fit parameters can be propagated up to the eikonal in the $q^2$- space. A systematic study of the effect of the experimental information at large values of the momentum transfer is developed and discussed in detail. We present statistical evidence that the imaginary part of the eikonal changes sign in the q^2- space and that the position of the zero decreases as the energy increases; after the position of the zero, the eikonal presents a minimum and then goes to zero through negative values. We discuss the applicability of our results in the phenomenological context, outlining some connections with nonperturbative QCD. A short review and a critical discussion on the main results concerning "model-independent" analyses are also presented.Comment: 18 pages, 17 figures, 4 tables, svjour.cls. Revised discussion on the proton's electromagnetic form factor and references added. To appear in Eur. Phys. J.

Chiral bosonization for non-commutative fields

A model of chiral bosons on a non-commutative field space is constructed and new generalized bosonization (fermionization) rules for these fields are given. The conformal structure of the theory is characterized by a level of the Kac-Moody algebra equal to $(1+ \theta^2)$ where $\theta$ is the non-commutativity parameter and chiral bosons living in a non-commutative fields space are described by a rational conformal field theory with the central charge of the Virasoro algebra equal to 1. The non-commutative chiral bosons are shown to correspond to a free fermion moving with a speed equal to $c^{\prime} = c \sqrt{1+\theta^2}$ where $c$ is the speed of light. Lorentz invariance remains intact if $c$ is rescaled by $c \to c^{\prime}$. The dispersion relation for bosons and fermions, in this case, is given by $\omega = c^{\prime} | k|$.Comment: 16 pages, JHEP style, version published in JHE

Psychosocial Screening in Disorders/Differences of Sex Development: Psychometric Evaluation of the Psychosocial Assessment Tool

© 2019 S. Karger AG, Basel. Background/Aims: Utilization of a psychosocial screener to identify families affected by a disorder/difference of sex development (DSD) and at risk for adjustment challenges may facilitate efficient use of team resources to optimize care. The Psychosocial Assessment Tool (PAT) has been used in other pediatric conditions. The current study explored the reliability and validity of the PAT (modified for use within the DSD population; PAT-DSD). Methods: Participants were 197 families enrolled in the DSD-Translational Research Network (DSD-TRN) who completed a PAT-DSD during a DSD clinic visit. Psychosocial data were extracted from the DSD-TRN clinical registry. Internal reliability of the PAT-DSD was tested using the Kuder-Richardson-20 coefficient. Validity was examined by exploring the correlation of the PAT-DSD with other measures of caregiver distress and child emotional-behavioral functioning. Results: One-third of families demonstrated psychosocial risk (27.9% Targeted and 6.1% Clinical level of risk). Internal reliability of the PAT-DSD Total score was high (α = 0.86); 4 of 8 subscales met acceptable internal reliability. A priori predicted relationships between the PAT-DSD and other psychosocial measures were supported. The PAT-DSD Total score related to measures of caregiver distress (r = 0.40, p \u3c 0.001) and to both caregiver-reported and patient self-reported behavioral problems (r = 0.61, p \u3c 0.00; r = 0.37, p \u3c 0.05). Conclusions: This study provides evidence for the reliability and validity of the PAT-DSD. Given variability in the internal reliability across subscales, this measure is best used to screen for overall family risk, rather than to assess specific psychosocial concerns

Anais...

RNPG, 2023. Editado por Regina Maria Villas Bôas de Campos Leite, Hugo Soares Kern